key: cord-0747399-8lmb5dfp
authors: Thakkar, Dhwanee; Rastogi, Neha; Ramzan, Mohammad; Yadav, Satya Prakash
title: COVID-19 in children with severe aplastic anemia
date: 2022-05-21
journal: nan
DOI: 10.1016/j.phoj.2022.05.004
sha: fac8d393df5ceb1d64ce2d787b9ab983a40aeddc
doc_id: 747399
cord_uid: 8lmb5dfp

Introduction Coronavirus disease 2019 (COVID-19) affects children but mostly has mild course. There is meagre published data on the impact of COVID-19 illness in children with Severe Aplastic anemia (SAA). We describe our experience of managing COVID-19 in children with SAA. Method Three children of SAA who developed SARS-CoV-2 infection are included in this study. Results Patient 1 was post Immunosuppressive therapy (IST) for SAA and had an asymptomatic course and uneventful recovery. Patient 2 was several months post IST with no response and had an asymptomatic COVID-19 illness but had delayed viral clearance, however he succumbed to bacterial sepsis soon after. Patient 3 was awaiting IST and while he contracted severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) infection, he had symptomatic COVID-19 illness followed by bacterial and fungal sepsis to which he succumbed. Conclusion: COVID-19 in children with SAA can be mild to fatal course and virus may have delayed clearance. It can lead to delay in therapy of SAA.

Introduction-The world is facing an unprecedented pandemic due to COVID-19 caused by SARS-CoV-2. This poses several challenges in the management of children suffering from life threatening conditions like SAA. While patients with SAA are more susceptible to infections due to neutropenia, the infections are likely to run a more severe course due to the immunosuppression caused by the treatment. 1, 2 However, experience with the COVID-19 illness has highlighted that the severity of the course of illness is linked more so with the hyperinflammatory state that the illness confers and the immune mediated multiorgan involvement and injury. 3 There is paucity of published data on how children with SAA fare when they contract SARS-CoV-2 infection. We describe here, our experience of illness in 3 children of SAA. Table 1 . During her COVID positive status, blood investigations were not done as she was asymptomatic and she was monitored by teleconsultations by phone twice a week. She is alive and healthy at last follow-up which is 8 months from the diagnosis of SAA and is transfusion independent. We acknowledge that ours is a small cohort of three children with AA who developed SARS-CoV-2 infection and COVID-19 illness. However, in the wake of meagre published literature on how these SAA children fare if they develop COVID-19 illness, we believe that our experience adds to important knowledge about the same. We resonate the expert consensus that definitive treatment should be delivered to these patients without delay and without the fear of severe illness should they happen to contract SARS-CoV-2 infection. However, we do believe that these children form a high-risk group for whom COVID-19 illness may add to the overall J o u r n a l P r e -p r o o f fragility and decline in the residual hematopoietic status and may contribute to adverse outcome.

Conflict of Interest: There are no conflicts of Interest

Coronavirus Disease 2019 and Children: What Pediatric Health Care Clinicians Need to Know

Coronavirus Disease 2019 in Children. Front Pediatr

COVID-19 in Immunosuppressed Children. Front Pediatr

Aplastic Anemia

COVID-19 infection in patients with severe aplastic anaemia

COVID-19 in a child with severe aplastic anemia. Pediatr Blood Cancer

First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia

SARS-CoV-2 infection coincident with newly diagnosed severe aplastic anemia: A report of two cases. Pediatr Blood Cancer

How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review

The Facts During the Third Epidemic

SARS-CoV-2 infection in aplastic anaemia

J o u r n a l P r e -p r o o f